Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Palonosetron in prevention of nausea and vomiting following highly emetogenic chemotherapy before haematopoietic stem cell transplantation- single centre experience

P Rzepecki, S Oborska

Ann Transplant 2009; 14(1): 74-74 :: ID: 880473

Abstract

Background: A clinical study of palonosetron was carried out to evaluate its
efficacy in preventing both acute and delayed emesis after high-dose chemotherapy [HDC] before hematopoietic stem cell transplantation [HSCT] by using a historical control group of patients treated with ondansetron as the comparative drug.
Material/Methods: 46 patients were evaluated [20- lymphoma and received BEAM as conditioning regimen; 16- relapsed germ cell tumour treated with CARBOPEC; 10- acute myeloid leukaemia received BuCY]. The severity of nausea was evaluated according to the following 4-grade scale: none (no
nausea); mild (slight nausea but no disruption to daily activities); moderate
(nausea and some disruption to daily activities);and severe (extreme nausea and severe disruption to daily activities).The emetic response rate was evaluated using the following criteria: complete (no emetic episode); major (1 to 2 episodes); minor (3 to 5 episodes); and failure (>5 episodes). The response rate of the study drugs was evaluated by the following 4-grade scale based on the condition of nausea and vomiting: highly effective, moderately effective, slightly effective and not effective.
Results: Patients treated with palonosetron had significantly higher response
rates than those receiving ondansetron during the both: acute and delayed
phases [highly moderately effective: acute phase 15% vs. 5% CARBOPEC; 70% vs. 35% BEAM and 32% vs. 20% BuCY; delayed phase: 60% vs. 30% BuCY; 100% vs. 50% BEAM and 25% vs. 10% CARBOPEC.
Conclusions: Single-dose palonosetron was more effective than ondansetron treatment in preventing acute and delayed nausea and vomiting following HDC before HSCT.

Keywords: Bone Marrow Transplantation, Stem Cell Transplantation

0 Comments

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358